Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mersana Therapeutics Inc
(NQ:
MRSN
)
2.040
+0.060 (+3.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mersana Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
September 12, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or...
Via
Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
September 01, 2022
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $4.28 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.5%, resulting in a loss of $52.22...
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 16, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 09, 2022
Via
Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
August 09, 2022
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.
Via
Benzinga
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
August 09, 2022
Via
Benzinga
Recap: Mersana Therapeutics Q1 Earnings
May 09, 2022
Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
August 10, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Via
Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 09, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
August 08, 2022
Via
Benzinga
Earnings Preview For Mersana Therapeutics
August 05, 2022
Mersana Therapeutics (NASDAQ:MRSN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Mersana...
Via
Benzinga
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Mersana Therapeutics's Return On Capital Employed Overview
June 03, 2022
According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26...
Via
Benzinga
Executives Buy Around $17M Of 5 Penny Stocks
May 19, 2022
The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their...
Via
Benzinga
Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug
May 19, 2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The...
Via
Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
May 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
April 18, 2022
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....
Via
Benzinga
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
68 Biggest Movers From Yesterday
April 19, 2022
Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 23, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...
Via
Benzinga
Looking Into Mersana Therapeutics's Return On Capital Employed
March 01, 2022
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in...
Via
Benzinga
Recap: Mersana Therapeutics Q4 Earnings
February 28, 2022
Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 16, 2022
On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...
Via
Benzinga
78 Biggest Movers From Friday
February 14, 2022
Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.